Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1125P is a noncoding RNA pseudogene derived from the U6 small nuclear RNA gene family[7][5]. U6 snRNAs are core components of the spliceosome, responsible for catalyzing intron removal during pre-mRNA splicing in eukaryotes[1][3]. The existence of numerous U6 pseudogenes in the human genome reflects the evolutionary importance and high conservation of U6 snRNA. Unlike the canonical U6 snRNA, pseudogenes like RNU6-1125P typically do not produce functional RNA molecules, nor do they encode proteins. However, research in pseudogene biology has shown that some pseudogenes can be transcribed, and in rare cases, their RNA transcripts may regulate gene expression by acting as decoys or sources of regulatory small RNAs[4]. There is currently no evidence that RNU6-1125P itself is functional, nor is it considered a therapeutic target, nor are there any drugs or biomarkers linked specifically to this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1125, pseudogene (RNU6-1125P).